Literature DB >> 25610600

Obesity-related pulmonary arterial hypertension in rats correlates with increased circulating inflammatory cytokines and lipids and with oxidant damage in the arterial wall but not with hypoxia.

David C Irwin1, Chrystelle V Garat2, Joseph T Crossno3, Paul S MacLean4, Timothy M Sullivan5, Paul F Erickson5, Matthew R Jackman6, Julie W Harral5, Jane E B Reusch7, Dwight J Klemm8.   

Abstract

Obesity is causally linked to a number of comorbidities, including cardiovascular disease, diabetes, renal dysfunction, and cancer. Obesity has also been linked to pulmonary disorders, including pulmonary arterial hypertension (PAH). It was long believed that obesity-related PAH was the result of hypoventilation and hypoxia due to the increased mechanical load of excess body fat. However, in recent years it has been proposed that the metabolic and inflammatory disturbances of obesity may also play a role in the development of PAH. To determine whether PAH develops in obese rats in the absence of hypoxia, we assessed pulmonary hemodynamics and pulmonary artery (PA) structure in the diet-resistant/diet-induced obesity (DR/DIO) and Zucker lean/fatty rat models. We found that high-fat feeding (DR/DIO) or overfeeding (Zucker) elicited PA remodeling, neomuscularization of distal arterioles, and elevated PA pressure, accompanied by right ventricular (RV) hypertrophy. PA thickening and distal neomuscularization were also observed in DIO rats on a low-fat diet. No evidence of hypoventilation or chronic hypoxia was detected in either model, nor was there a correlation between blood glucose or insulin levels and PAH. However, circulating inflammatory cytokine levels were increased with high-fat feeding or calorie overload, and hyperlipidemia and oxidant damage in the PA wall correlated with PAH in the DR/DIO model. We conclude that hyperlipidemia and peripheral inflammation correlate with the development of PAH in obese subjects. Obesity-related inflammation may predispose to PAH even in the absence of hypoxia.

Entities:  

Keywords:  hyperlipidemia; hypoxia; inflammation; insulin resistance; obesity; oxidant damage; pulmonary hypertension

Year:  2014        PMID: 25610600      PMCID: PMC4278624          DOI: 10.1086/678510

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  62 in total

1.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance.

Authors:  Timothy R Koves; John R Ussher; Robert C Noland; Dorothy Slentz; Merrie Mosedale; Olga Ilkayeva; James Bain; Robert Stevens; Jason R B Dyck; Christopher B Newgard; Gary D Lopaschuk; Deborah M Muoio
Journal:  Cell Metab       Date:  2008-01       Impact factor: 27.287

Review 2.  Adipocytokines in obesity and metabolic disease.

Authors:  Haiming Cao
Journal:  J Endocrinol       Date:  2014-01-08       Impact factor: 4.286

Review 3.  Redox modulation of insulin signaling and endothelial function.

Authors:  Raymond Christon; Olivier Drouin; Andre Marette
Journal:  Antioxid Redox Signal       Date:  2005 Jul-Aug       Impact factor: 8.401

4.  Lipid partitioning, incomplete fatty acid oxidation, and insulin signal transduction in primary human muscle cells: effects of severe obesity, fatty acid incubation, and fatty acid translocase/CD36 overexpression.

Authors:  Jill A Bell; Melissa A Reed; Leslie A Consitt; Ola J Martin; Kimberly R Haynie; Matthew W Hulver; Deborah M Muoio; G Lynis Dohm
Journal:  J Clin Endocrinol Metab       Date:  2010-04-28       Impact factor: 5.958

5.  Interleukin-6 induces cellular insulin resistance in hepatocytes.

Authors:  Joseph J Senn; Peter J Klover; Irena A Nowak; Robert A Mooney
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

6.  Pulmonary and cardiovascular complications of obesity: an autopsy study of 76 obese subjects.

Authors:  Abida K Haque; Swarupa Gadre; Jerrod Taylor; Sajid A Haque; Daniel Freeman; Alex Duarte
Journal:  Arch Pathol Lab Med       Date:  2008-09       Impact factor: 5.534

7.  Adiponectin ameliorates hypoxia-induced pulmonary arterial remodeling.

Authors:  Yasuhiko Nakagawa; Ken Kishida; Shinji Kihara; Tohru Funahashi; Iichiro Shimomura
Journal:  Biochem Biophys Res Commun       Date:  2009-03-09       Impact factor: 3.575

Review 8.  Prostanoid and isoprostanoid pathways in atherogenesis.

Authors:  Domenico Praticò
Journal:  Atherosclerosis       Date:  2008-04-29       Impact factor: 5.162

Review 9.  Obesity and respiratory diseases.

Authors:  A T Murugan; G Sharma
Journal:  Chron Respir Dis       Date:  2008       Impact factor: 2.444

Review 10.  Recent advances in obesity hypoventilation syndrome.

Authors:  Babak Mokhlesi; Aiman Tulaimat
Journal:  Chest       Date:  2007-10       Impact factor: 9.410

View more
  8 in total

Review 1.  Pulmonary vascular dysfunction in metabolic syndrome.

Authors:  Conor Willson; Makiko Watanabe; Atsumi Tsuji-Hosokawa; Ayako Makino
Journal:  J Physiol       Date:  2018-09-12       Impact factor: 5.182

2.  The substitution of SERCA2 redox cysteine 674 promotes pulmonary vascular remodeling by activating IRE1α/XBP1s pathway.

Authors:  Weimin Yu; Gang Xu; Hui Chen; Li Xiao; Gang Liu; Pingping Hu; Siqi Li; Vivi Kasim; Chunyu Zeng; Xiaoyong Tong
Journal:  Acta Pharm Sin B       Date:  2022-01-05       Impact factor: 14.903

3.  Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice.

Authors:  Balram Neupane; Akylbek Sydykov; Kabita Pradhan; Christina Vroom; Christiane Herden; Srikanth Karnati; Hossein Ardeschir Ghofrani; Sergey Avdeev; Süleyman Ergün; Ralph Theo Schermuly; Djuro Kosanovic
Journal:  Respir Res       Date:  2020-06-03

4.  BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.

Authors:  Breanne E McCarthy; Robyn L McClelland; Dina H Appleby; Jude S Moutchia; Jasleen K Minhas; Jeff Min; Jeremy A Mazurek; K Akaya Smith; Jason S Fritz; Steven C Pugliese; Ryan J Urbanowicz; John H Holmes; Harold I Palevsky; Steven M Kawut; Nadine Al-Naamani
Journal:  Chest       Date:  2022-03-03       Impact factor: 10.262

5.  Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR).

Authors:  Jeff Min; Rui Feng; David Badesch; Erika Berman-Rosenzweig; Charles Burger; Murali Chakinala; Teresa De Marco; Jeremy Feldman; Anna Hemnes; Evelyn M Horn; Matthew R Lammi; Stephen Mathai; John W McConnell; Kenneth Presberg; Jeffrey Robinson; Jeffrey Sager; Oksana A Shlobin; Marc Simon; Thenappan Thenappan; Corey Ventetuolo; Nadine Al-Naamani
Journal:  Ann Am Thorac Soc       Date:  2020-10-21

6.  Elevated pulmonary arterial pressure in Zucker diabetic fatty rats.

Authors:  Daniel Morales-Cano; Maria Callejo; Bianca Barreira; Gema Mondejar-Parreño; Sergio Esquivel-Ruiz; Sonia Ramos; María Ángeles Martín; Angel Cogolludo; Laura Moreno; Francisco Perez-Vizcaino
Journal:  PLoS One       Date:  2019-01-28       Impact factor: 3.240

7.  miR‑126a‑5p‑Dbp and miR‑31a‑Crot/Mrpl4 interaction pairs crucial for the development of hypertension and stroke.

Authors:  Qini Zhao; Huan Sun; Liquan Yin; Libo Wang
Journal:  Mol Med Rep       Date:  2019-09-12       Impact factor: 2.952

Review 8.  Obesity, estrogens and adipose tissue dysfunction - implications for pulmonary arterial hypertension.

Authors:  Kirsty M Mair; Rosemary Gaw; Margaret R MacLean
Journal:  Pulm Circ       Date:  2020-09-18       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.